BACKGROUND Focal or total skin radiation therapy can be used to treat mild to refractory cutaneous T-cell lymphoma. OBJECTIVE To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma. METHODS Retrospective, single-institution review of outcomes for skin-directed radiation therapy. RESULTS Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation. LIMITATIONS Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number). CONCLUSIONS Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.

中文翻译：

---

针对皮肤淋巴瘤的皮肤定向放射疗法：梅奥诊所的经验。

背景技术局部或全皮肤放射疗法可用于治疗轻度至难治性皮肤T细胞淋巴瘤。目的报道放射治疗对皮肤T细胞淋巴瘤的广泛治疗益处。方法对皮肤定向放射治疗的结果进行回顾性，单机构回顾。结果皮肤定向放射治疗在治疗后无论其受累程度，严重程度，组织病理学亚型，剂量或分级如何，均显示99％的缓解率和80％的完全缓解率。总体现场复发率为15％，中位复发时间为296天（范围为1-1884天）。局部和低剂量方案与疾病反应和罕见毒性相似。治疗后继发性皮肤癌的短期发生率与无辐射的患者人群的预期发病率相当。局限性与患者总数相比，治疗疗程总数大。治疗方案的异质混合（剂量或分数的标准化）。结论放射疗法是用于适当地选择患者皮肤T细胞淋巴瘤良好耐受的治疗选择。